Heidi A. Neubauer
Heidi A. Neubauer
Verified email at vetmeduni.ac.at
Cited by
Cited by
Roles, regulation and inhibitors of sphingosine kinase 2
HA Neubauer, SM Pitson
The FEBS journal 280 (21), 5317-5336, 2013
Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
B Wingelhofer, HA Neubauer, P Valent, X Han, SN Constantinescu, ...
Leukemia, doi: 10.1038/s41375-018-0117-x., 2018
Tumor target amplification: Implications for nano drug delivery systems
K Seidi, HA Neubauer, R Moriggl, R Jahanban-Esfahlan, T Javaheri
Journal of Controlled Release 275, 142-161, 2018
An oncogenic role for sphingosine kinase 2
HA Neubauer, DH Pham, JR Zebol, PAB Moretti, AL Peterson, ...
Oncotarget 7 (40), 64886, 2016
STAT3 and STAT5 activation in solid cancers
S Igelmann, HA Neubauer, G Ferbeyre
Cancers 11 (10), 1428, 2019
Direct targeting options for STAT3 and STAT5 in cancer
A Orlova, C Wagner, ED de Araujo, D Bajusz, HA Neubauer, M Herling, ...
Cancers 11 (12), 1930, 2019
NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth
K Seidi, R Jahanban-Esfahlan, H Monhemi, P Zare, B Minofar, ADF Adli, ...
Oncogene, doi:10.1038/s41388-018-0213-4., 2018
Structural and functional consequences of the STAT5B N642H driver mutation
ED de Araujo, F Erdogan, HA Neubauer, D Meneksedag-Erol, ...
Nature communications 10 (1), 1-15, 2019
CIB2 negatively regulates oncogenic signaling in ovarian cancer via sphingosine kinase 1
W Zhu, KE Jarman, NA Lokman, HA Neubauer, LT Davies, BL Gliddon, ...
Cancer research 77 (18), 4823-4834, 2017
Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers
M Brachet-Botineau, M Polomski, HA Neubauer, L Juen, D Hédou, ...
Cancers 12 (1), 240, 2020
Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma
HA Neubauer, MN Tea, JR Zebol, BL Gliddon, C Stefanidis, PAB Moretti, ...
Oncogene 38 (8), 1151-1165, 2019
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas
A Orlova, B Wingelhofer, HA Neubauer, B Maurer, A Berger-Becvar, ...
Expert opinion on therapeutic targets 22 (1), 45-57, 2018
The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5
D Kadekar, R Agerholm, J Rizk, HA Neubauer, T Suske, B Maurer, ...
The Journal of clinical investigation 130 (5), 2496-2508, 2020
Structural implications of STAT3 and STAT5 SH2 domain mutations
ED de Araujo, A Orlova, HA Neubauer, D Bajusz, HS Seo, ...
Cancers 11 (11), 1757, 2019
Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1
JA Powell, MR Pitman, JR Zebol, PAB Moretti, HA Neubauer, LT Davies, ...
Biochemical Journal 476 (21), 3211-3226, 2019
STAT5 is expressed in CD34+/CD38− stem cells and serves as a potential molecular target in ph-negative myeloproliferative neoplasms
E Hadzijusufovic, A Keller, D Berger, G Greiner, B Wingelhofer, ...
Cancers 12 (4), 1021, 2020
The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis
A Orlova, HA Neubauer, R Moriggl
haematologica 104 (10), 1907, 2019
Cell metabolism control through O-GlcNAcylation of STAT5: A full or empty fuel tank makes a big difference for cancer cell growth and survival
M Rauth, P Freund, A Orlova, S Grünert, N Tasic, X Han, HB Ruan, ...
International journal of molecular sciences 20 (5), 1028, 2019
Thyroid and androgen receptor signaling are antagonized by μ‐Crystallin in prostate cancer
O Aksoy, J Pencik, M Hartenbach, AA Moazzami, M Schlederer, T Balber, ...
International journal of cancer 148 (3), 731-747, 2021
Validation of commercially available sphingosine kinase 2 antibodies for use in immunoblotting, immunoprecipitation and immunofluorescence
HA Neubauer, SM Pitson
F1000Research 5, 2825, 2016
The system can't perform the operation now. Try again later.
Articles 1–20